AstraZeneca Gains US Priority Review for IMFINZI in MIBC
WILMINGTON, Del. — September 25, 2026 AstraZeneca announced that the US Food and Drug Administration (FDA) has accepted and...
Muscle-Invasive Bladder Cancer
Advertisement
Merck Gains Positive EU CHMP Opinion for KEYTRUDA and Padcev
RAHWAY, N.J. — September 18, 2026 Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human...
Astellas PADCEV and Keytruda Gain Positive CHMP Opinion
Tokyo, Japan, September 17, 2026 Astellas Pharma Inc. has announced that the European Medicines Agency’s Committee for Medicinal Products...
Natera Submits Signatera to Japan PMDA for MIBC Approval
AUSTIN, Texas, August 5, 2026 Natera, Inc. has submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA)...
Pfizer Canada Secures PADCEV Plus KEYTRUDA Approval
KIRKLAND, Quebec, Canada, June 29, 2026 Pfizer Canada ULC announced that Health Canada has approved PADCEV® (enfortumab vedotin) in...
Advertisements
Merck’s KEYTRUDA and Padcev Combination Shows Strong Survival Benefit Ahead of EU Approval
RAHWAY, New Jersey, May 24, 2026 Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human...
Astellas’ PADCEV Combo Wins CHMP Support in MIBC
Tokyo, Japan – May 22, 2026 Astellas Pharma Inc. announced that the European Medicines Agency’s Committee for Medicinal Products...
Mabwell Showcases Strong 9MW2821 Bladder Cancer Data at ASCO 2026
SHANGHAI, China, 22 May 2026 Mabwell announced that new clinical data for its investigational Nectin-4-targeting antibody-drug conjugate (ADC) 9MW2821...
Advertisement
